Abstracts tagged "Biomarkers"

Abstract Number: 1360 • 2015 ACR/ARHP Annual Meeting
Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease
Christine McDonald¹, Min Shen¹, Amrita Kabi¹, Craig Homer¹ and Qingping Yao², ¹Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Yao Syndrome (YS) is a systemic autoinflammatory disease formerly termed Nucleotide-binding oligomerization domain 2 (NOD2)-associated AutoInflammatory Disease (NAID) due to its association with specific…
Abstract Number: 1849 • 2015 ACR/ARHP Annual Meeting
Serum Axl and Tumor Necrosis Factor Receptor II Portend Long-Term Renal Outcome in Lupus Nephritis
Ioannis Parodis¹, Huihua Ding², Agneta Zickert¹, Chandra Mohan² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). Renal biopsy is gold standard for evaluation of renal activity and damage.…
Abstract Number: 2401 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of Two Osteoarthritis Phenotypes Applying Two Clinically Tested Biomarkers
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen³, Bente J. Riis², Claus Christiansen², Morten Asser Karsdal¹ and Jeppe Andersen², ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The osteoarthritis (OA) population is heterogeneous and it is therefore difficult to target all patients with the same intervention. Thus there is a clinical…
Abstract Number: 2797 • 2015 ACR/ARHP Annual Meeting
Identification of Serum Biomarker for the Glandular Dysfunction of Primary Sjögren’s Syndrome
Ayumi Nishikawa¹, Katsuya Suzuki¹, Yoshiaki Kassai², Yuumi Gotou³, Takahiro Miyazaki⁴, Maiko Takiguchi⁴, Rimpei Morita⁵, Akihiko Yoshimura⁵ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan, ⁵Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by dry eye and mouth. Measurements of un-stimulated salivary flow and Schirmer’s test are…
Abstract Number: 3236 • 2015 ACR/ARHP Annual Meeting
Circulating Cytokine/Chemokine Concentrations Predict Cancer Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Jeremy Sokolove², William H. Robinson³, Geoffrey M. Thiele⁴, Apar K. Ganti⁵, Harlan Sayles⁶, Kaleb Michaud⁷, Liron Caplan⁸, Lisa A. Davis⁸, Grant W. Cannon⁹, Brian Sauer¹⁰, E. Blair Solow¹¹, Andreas Reimold¹², Gail S. Kerr¹³, Pascale Schwab¹⁴, Joshua F. Baker¹⁵ and Ted R. Mikuls¹⁶, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Oncology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁸Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹²Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹³VAMC, Georgetown University, Washington, DC, ¹⁴Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁵Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammation and the dysregulated expression of pro-inflammatory cytokines / chemokines (CK). Chronic inflammation has also been implicated…
Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Alexandre Osborne¹, Nathalie Carrier², Artur J de Brum-Fernandes³, Patrick Liang³, Ariel Masetto⁴ and Gilles Boire³, ¹Clinical Sciences Program, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…
Abstract Number: 821 • 2015 ACR/ARHP Annual Meeting
Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis
Kazunori Kato¹, Tomoko Ito², Naoto Tamura², Sayuri Okuda¹, Masakazu Matsushita², Kurisu Tada², Ken Yamaji² and Yoshinari Takasaki², ¹Department of Biomedical Engineering, Toyo University, Saitama, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: CD146 is a transmembrane glycoprotein belonging to Ig-superfamily. Human endothelial cells, activated fibroblasts and Th17 cells express CD146 that involved in angiogenesis, fibrosis and…
Abstract Number: 1375 • 2015 ACR/ARHP Annual Meeting
S100A8/A9, a Serum and Imaging Biomarker for Assessing Joint Inflammation and Destruction in Experimental Seronegative Arthritis
Edwin J. W. Geven¹, Shahla Abdolahi-Roodsaz¹, Annet Sloetjes¹, Marije I. Koenders¹, Dirk Föll², Johannes Roth³, Thomas Vogl³ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ³Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Seronegative joint diseases such as psoriatic arthritis and juvenile idiopathic arthritis are characterized by the lack of autoantibodies, potent biomarkers used for predicting disease…
Abstract Number: 1850 • 2015 ACR/ARHP Annual Meeting
Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus
Eun-Ju Lee^1,2, Seokchan Hong³, Doo-Ho Lim¹, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Asan Institute for Life Science, Asan Medical Center, Seoul, South Korea, ³Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Systemic lupus erythematous (SLE) is a multisystem autoimmune inflammatory disease. Lupus nephritis (LN) is one of the most serious complications in patients with SLE.…
Abstract Number: 2446 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course
AnneMarie C. Brescia¹, Megan M. Simonds², Kathleen E. Sullivan³ and Carlos D. Rose⁴, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE, ³Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Children with oligoarticular juvenile idiopathic arthritis (JIA) who have an extended course (recruitment of 5 or more joints after 6 months of disease) have…
Abstract Number: 2803 • 2015 ACR/ARHP Annual Meeting
Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Zana Brkic¹, Paul L. van Daele^1,3, P. Martin van Hagen^1,3, Peter J. van der Spek², Hemmo A. Drexhage¹, Wan-Fai Ng⁴ and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Bioinformatics, Erasmus Medical Center, Rotterdam, Netherlands, ³Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease with a large heterogeneity in clinical phenotype. The IFN type I signature is present in…
Abstract Number: 3256 • 2015 ACR/ARHP Annual Meeting
Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients
Claudio Carini¹, Aroul Ramadass², Philip Jordan², Ewan Hunter², Alexandre Akoulitchev², Iain. B. McInnes³, Carl. S. Goodyear³ and Scottish Early Rheumatoid Arthritis Inception Cohort Investigators, ¹35 Cambridgepark Drive, Pfizer, Cambridge, MA, ²Oxford Biodynamics, Oxford, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In early rheumatoid arthritis (RA), it is not possible to predict response to first line DMARDs (e.g. methotrexate (MTX)) and as such treatment decisions…
Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting
Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
María López-Lasanta¹, Antonio Julià¹, Joan Maymo², Benjamin Fernandez Gutierrez³, Inmaculada Ureña⁴, Francisco J. Blanco⁵, Juan D. Cañete⁶, Mercedes Alperi-López⁷, Alejandro Olivé⁸, Hector Corominas⁹, Jesús Tornero¹⁰, Alba Erra¹¹, Miriam Almirall¹², Nuria Palau¹³, Ana M. Ortiz Garcia¹⁴, Gabriela Avila¹³, Luis Rodriguez-Rodriguez¹⁵, Arnald Alonso¹, Raül Tortosa¹, Isidoro González-Alvaro¹⁶ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, Hospital del Mar, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁸Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹¹Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, ¹²Rheumatology Department, Hospital del Mar, Barcelona, Spain, ¹³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
Abstract Number: 545 • 2015 ACR/ARHP Annual Meeting
Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹ and Huaping Wang², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Baseline sIL-2Rα levels predicted total mortality in both pre-RA and matched CN subjects, in a preceding prospective cohort study (A&R 2010; 62:S19). Now, the…
Abstract Number: 847 • 2015 ACR/ARHP Annual Meeting
Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension
Silvia Laura Bosello¹, Giacomo De Luca¹, Franca Forni², Clara Di Mario³, Federico parisi¹, Giovanni Canestrari¹, Giorgia Berardi¹, Manuela Rucco¹, Francesca Gabrielli⁴, Leonarda Galiuto⁴, Francesco Loperfido⁴ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Laboratory Medicine, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁴Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy
Background/Purpose: Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represents one of the leading cause of death in these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].